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Background: The molecular mechanisms underlying dysregulation of microRNAs have been documented in
nasopharyngeal carcinoma (NPC). Our previous study demonstrated that plasma miR-124 was down-regulated in
NPC using microarray analysis and quantitative PCR validation. Though growing studies showed that down-regulated
miR-124 was closely related to tumourigenesis in various types of cancers, the role of miR-124 in NPC remains
largely unknown.
Methods: The expression level of miR-124 was evaluated in NPC cell lines and patient specimens using quantitative
reverse transcription-PCR (Real-time qPCR). The clinicopathological significance of the resultant data was later analyzed.
Then, we explored the role of miR-124 in NPC tumorigenesis by in vitro and in vivo experiments. Homo sapiens forkhead
box Q1 (Foxq1) was confirmed as a novel direct target gene of miR-124 by the dual-luciferase assay and western bolt.
Results: We found that miR-124 was commonly down-regulated in NPC specimens and NPC cell lines. The expression of
miR-124 was inversely correlation with clinical stages and marked on T stages. Then, the ectopic expression of miR-124
dramatically inhibited cell proliferation, colony formation, migration and invasion in vitro, as well as tumor growth and
metastasis in vivo. Furthermore, we identified Foxq1 as a novel direct target of miR-124. Functional studies showed that
knockdown of Foxq1 inhibited cell growth, migration and invasion, whereas Foxq1 overexpression partially rescued the
suppressive effect of miR-124 in NPC. In clinical specimens, Foxq1 was commonly up-regulated in NPC, and the level
increased with clinical stages and T stages. Additionally, the level of Foxq1 was inversely correlated with miR-124.
Conclusions: Our results demonstrate that miR-124 functions as a tumor-suppressive microRNA in NPC, and that
its suppressive effects are mediated chiefly by repressing Foxq1 expression. MiR-124 could serve as an independent
biomarker to identify patients with different clinical characteristics. Therefore, our findings provide valuable clues toward
the understanding the of mechanisms of NPC pathogenesis and provide an opportunity to develop new effective clinical
therapies in the future.
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Nasopharyngeal carcinoma (NPC) is a non-lymphomatous
squamous cell carcinoma derived from epithelial cells lining
on the nasopharynx [1]. The characteristics are highly ma-
lignant local invasion and early distant metastasis, and the
prevalence of NPC is low globally but high in southern
China and Southeast Asia [2,3]. The radiotherapy proves to
be the most sensitive and effective treatment, but the* Correspondence: li321162@qq.com
†Equal contributors
1Department of Otorhinolaryngology-Head and Neck Surgery, Nanfang Hospital,
Southern Medical University, Guangzhou, Guangdong 510515, China
Full list of author information is available at the end of the article
© 2014 Peng et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.average 5year survival rate for NPC patients remains at
70% [1,3-5]. During tumorigenesis and progression, mul-
tiple genetic and epigenetic abnormalities synergistically
disrupt normal cell function, thus contributing to NPC
pathogenesis [6-9]. Until now, the underlying mechanisms
of NPC tumorigenesis are not completely understood.
Therefore, further investigation is urgently needed.
MicroRNAs (miRs) are small non-coding RNAs which
function as endogenous regulatory RNA molecules and
modulate many physiological and pathological processes
through down-regulating target genes [10,11]. There is a
large body of evidence indicating that abnormal miRNAstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tumor progression [12]. To date, multiple miRNAs have
been shown to be dysregulated in NPC, such as miR-
26a, miR-9, miR-10b, miR-144 and miR-214 which
contributed to the development and progression of NPC
[13-20]. Our previous study demonstrated for the first
time that plasma miR-124 was down-regulated in NPC
[21]. However, the role of miR-124 in NPC and the
molecular mechanisms in which miR-124 exerts its func-
tions remain largely unknown.
Human Foxq1 is first identified to encode a protein of
403 amino acids and belongs to the family of the Fox
transcription factors (previously called HNF-3/ forkhead
transcription factors) in 2001 [22]. The biological func-
tion of Foxq1 has been clearly identified in hair follicle
differentiation [23,24]. Previous studies have found that
Foxq1 is widely expressed at the mRNA level in murine
tissues, with particularly high expression levels in the blad-
der and stomach [25]. Recent several studies reported that
Foxq1 was markedly overexpressed in colorectal cancer
and glioma, which enhanced tumorigenicity and tumor
growth in vivo [26,27]. Furthermore, Foxq1 was also in-
volved in epithelial-mesenchymal transition regulation by
suppressing E-cadherin transcription, and associated with
aggressive cancer phenotype [14,15]. However, whether
Foxq1 expression contributes to NPC development and
progression is not clear.
In this study, we investigated the potential involvement of
miR-124 in NPC. We examined the expression level of
miR-124 in human NPC cells and tissues and tested its ef-
fects on cell growth, migration and invasion. In addition,
we also investigated a potential role of miR-124 on NPC
tumorigenesis and tumor metastasis in murine models.
Finally, we explored the underlying mechanism of miR-124
functions in NPC. Our study will provide a better under-
standing of NPC pathogenesis.
Results
MiR-124 was down-regulated in NPC cell lines and clinical
specimens and associated with advanced clinical stage
To study the expression level of miR-124 in NPC, a
panel of NPC cell lines was first analyzed by Real-time
PCR. Compared with the immortalized nasopharyngeal
epithelial cell line NP69, the basal expression level of
miR-124 was generally down regulated in 7 NPC cell
lines (5-8 F, 6-10B, CNE1, CNE2, HONE-1, C666-1
and Sune-1) (Figure 1A).
We further tested the expression level of miR-124 in
178 primary NPC tissues and 55 non-cancer nasophar-
yngitis biopsy samples to analyze the clinicopathologic
significance of miR-124. The relationship between the
miR-124 expression level and clinicopathologic charac-
teristics in NPC patients were summarized in Table 1.
MiR-124 was not significantly associated with age andgender of the patients. Consistent with the result of the
NPC cell lines, the average expression level of miR-124
was decreased in NPC tissue compared with non-cancer
biopsy samples (Figure 1B). We found that miR-124 ex-
pression was higher in stage I, whereas stages II-IV had
lower levels, showing a significant correlation of miR-
124 with clinical stages (Figure 1C). Furthermore, we
found that the miR-124 expression was higher in stage
T1, whereas stages T2-T4 had lower levels, showing a
significant correlation of miR-124 with T stage (Figure 1D).
In addition, we found that the level of miR-124 was lower
in distance metastasis tissues compared with local metasta-
sis tissues (Figure 1E). Taken together, these data provided
strong evidence that miR-124 expression was closely related
to the progression and clinicopathologic features of NPC.
On the basis of these results, we focused on miR-124 for
further functional studies to evaluate its roles in NPC
pathogenesis.
MiR-124 suppressed the proliferative, migratory and
invasive capacities of NPC cells
To determine the role of miR-124, we transfected the
NPC cell lines 5-8 F and 6-10B with miR-124 mimics
and miR-Ctrl. The up-regulated expression of miR-124
was confirmed by Real-time PCR (Figure 2A). CCK-8
array was utilized to evaluate cell proliferative capacity.
These results showed that ectopic expression of miR-124
could dramatically repress the cell growth of 5-8 F and
6-10B cells respectively (Figure 2B and C). Then, we
tested the cell cycle distribution. The results demon-
strated that ectopic expression of miR-124 arrest G0 +
G1 phase and decreased S phase in 5-8 F and 6-10B cells
compared with miR-Ctrl (Figure 3A). After analyzing the
proliferation capacity of miR-124, we investigated the
cell migration and invasion capacities. Migration and in-
vasion arrays demonstrated that miR-124 overexpression
inhibited cell migration and invasion compared with
miR-Ctrl (Figure 2E, F, G and H).
To further investigate colony formation capacity, we
used lentiviral vectors to stably up-regulate the expression
level of miR-124 in 5-8 F and 6-10B cell lines (Figure 3B).
Colony formation assay was performed to evaluate cell
growth. Similar results indicated that miR-124 inhibited the
colony formation ability in lv-miR-124/5-8 F and lv-
miR-124/6-10B cells compared with lv-miR-Ctrl cells
respectively (Figure 3C and D). Above all, these results
supported that ectopic expression of miR-124 inhibited
cell growth, colony formation, migration and invasion
in NPC cell lines in vitro.
MiR-124 inhibited tumor growth and metastasis in vivo
To determine whether miR-124 could affect tumor growth
in vivo. Lv-miR-124/5-8 F cells and lv-miR-Ctrl cells were
used for evaluating the effect of miR-124 overexpression on
Figure 1 The expression level of miR-124 was reduced in NPC cell lines and clinical specimens. A, The expression of miR-124 was reduced
in NPC cell lines. B, the average expression level of miR-124 in human NPC specimens compared with non-cancer biopsy samples. C, miR-124
expression was higher in stage I, whereas stages II-IV had lower levels. D, miR-124 expression was higher in stage T1, whereas stages T2-T4 had
lower levels. E. The expression level of mir-124 in the distance metastasis was lower than in the local metastasis. Statistical analysis was performed
using the nonparametric tests (B) and the one-way ANOVA (C, D and E). *, P < 0.05, **, P < 0.01.
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5-8 F or lv-miR-Ctrl/5-8 F cells subcutaneously in nude
mice respectively (n = 6 per group). As shown in Figure 3E,
lv-miR-124/5-8 F cells resulted in an approximately 2.68-
fold decrease in tumor size relative to lv-miR-Ctrl/5-8 F
cells after 15 days (Figure 3F, P < 0.05). After the tumors
were dissected and weighed, the results of tumor weight
were similar to results of tumor volume (Figure 3G and H).
The expression levels of miR-124 were examined after the
tumors were dissected (Additional file 1: Figure S1A). Thus,
these results showed that miR-124 suppressed tumor prolif-
eration capacity in vivo. We also showed that both the
staining intensity and the number of hyperproliferative Ki-
67+ and PCNA+ tumor cells were significantly decreased
compared with control (Figure 3I and Additional file 2:
Table S1; P < 0.05).
To further investigate the metastatic effect of miR-124
in vivo, primary tumors were established by direct injec-
tion of lv-miR-124/5-8 F or lv-miR-Ctrl/5-8 F cells intothe liver. Twenty-five days after transplantation, the
mice were killed and the livers and lungs were dissected
for macroscopic and microscopic histology. Livers and
lungs of mice bearing miR-124-expressing 5-8 F tumors
harbored statistically significantly fewer microscopic and
macroscopic metastases than those of mice bearing
mock-infected 5-8 F tumors (P < 0.05; Figure 4A-D). The
expression levels of miR-124 were examined after the
tumors were dissected from the livers (Additional file 1:
Figure S1B).
MiR-124 down-regulated the expression of Foxq1 by
directly targeting its 3′-UTR
To investigate the molecular mechanism for the prolif-
eration, migration and invasion of suppression by miR-
124 in NPC cells, we focused on 27 possible target
genes of mir-124 by utilizing bioinformatic analysis.
The selected target genes have been verified that
could affect tumor growth or metastasis in the website
Table 1 The relationship between miR-124 expression
and clinicopathological parameters in 178 NPC patients
Variable No. Median expression of miR-124 P
High expression Low expression
Age, year 0.188
<45 95 46 (48.4%) 49 (51.6%)
≥45 83 43 (51.8%) 40 (49.2%)
Gender 0.749
Male 120 57 (47.5%) 63 (52.5%)
Female 58 32 (55.1%) 26 (44.9%)
T status <0.001
T1 34 34 (100%) 0 (0%)
T2 42 33 (78.6%) 9 (21.4%)
T3 58 18 (31%) 40 (69%)
T4 44 6 (13.6%) 38 (86.4%)
N status 0.148
N0 16 10 (62.5%) 6 (37.5%)
N1 80 44 (55%) 36 (45%)
N2 60 27 (45%) 33 (55.0%)
N3 22 8 (36.4%) 14 (63.6%)
M status 0.114
M0 166 82 (50%) 84 (50%)
M1 12 7 (58.0%) 5 (42.0%)
Stage
I 5 5 (100%) 0 (0%) <0.001
II 37 33 (89.1%) 4 (10.8%)
III 70 35 (50%) 35 (50%)
IV 60 16 (26.7%) 44 (73.3%)
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targets were validated by RT-qPCR in lv-miR-124/5-8 F
cells. The result of RT-qPCR showed that the expression
level of Foxq1 decreased more significantly, compared
with other 26 possible target genes (Additional file 3:
Figure S2A). Finally, we selected Foxq1 gene as the target
gene of miR-124. Foxq1 is highly conserved among differ-
ent species, whose 3′-UTR of mRNA contained a comple-
mentary site for the seed region of miR-124 (Figure 5A).
Real-time PCR and western blot was performed to detect
the expression level of Foxq1, and the results showed that
Foxq1 was up-regulated in 7 NPC cell lines compared with
NP69 (Figure 5B and C). Then we analyzed the the mRNA
and protein level of Foxq1 after transfected lv-miR-124
into 5-8 F and 6-10B cell lines. As shown in Figure 5D
and Additional file 3: Figure S2B, Foxq1 was down-
regulated after transfected lv-miR-124.
To further confirm that Foxq1 was a direct target of
miR-124, dual-luciferase assay was performed. The tar-
get region sequence of Foxq1 3′-UTR (wt 3′-UTR) orthe mutant sequence (mut 3′-UTR) was cloned into a
luciferase reporter vector (Figure 5E). These recombin-
ant vectors were co-transfected with miR-124 mimics or
miR-Ctrl into 5-8 F cell line. The results showed that
miR-124 could down-regulated the luciferase activity of
the Foxq1 wt 3′-UTR construct (Figure 5F, lanes 1 and
2;P < 0.01). The activity of mut3′-UTR vector was un-
affected by a simultaneous transfection with miR-124
(Figure 5F, lanes 3 and 4). Moreover, miR-Ctrl did not
significantly affect the luciferase activity of either the wt
or mut 3′-UTR construct (Figure 5F, lanes 5 and 6).
The same results were obtained in HEK 293 T cell line
(Additional file 3: Figure S2C). In summary, these
results strongly suggested that miR-124 directly regu-
lated Foxq1 in NPC cell lines.
Overexpression of Foxq1 could partially rescue the
suppression of miR-124
To explore the function of Foxq1 in NPC cell lines, Foxq1-
siRNAs were transfected into 5-8 F cell lines. Real-time
PCR was confirmed that the Foxq1 mRNA level expression
was down-regulated compared with miR-Ctrl after trans-
fected (Additional file 4: Figure S3A). CCK8 array showed
that Foxq1 silencing inhibited the proliferation (Additional
file 4: Figure S3B). Furthermore, migration and invasion ar-
rays obtained the same results that knockdown of Foxq1
repressed the migration and invasion capacities of 5-8 F
cells (Additional file 4: Figure S3C and D). According to
these results, Foxq1 functioned as a potential oncogene in
NPC cell lines.
To elucidate whether the suppressive effect of miR-
124 was mediated by repression of Foxq1 in NPC cells,
we performed gain-of-function and loss-of-function
studies. First, we silenced Foxq1 to investigate whether
the reduced expression of Foxq1 could mimic the sup-
pressive effect of miR-124. 5-8 F cells were transfected
with siRNA-Foxq1 or miR-124 mimics. The Foxq1 pro-
tein expression of siRNA-Foxq1/5-8F and miR-124/5-8F
were down-regulated compare with siRNA-Ctrl/5-8F
(Figure 6D). Then, we examined cell proliferative, migra-
tory and invasive capacities. As shown in Figure 6A-C,
Foxq1 knockdown led to significant suppressive effects,
similar to those induced by miR-124 (P < 0.01). The
similar results were obtained in 6-10B cell lines (Additional
file 4: Figure S3E-G). Subsequently, we evaluated whether
ectopic expression of Foxq1 could rescue the suppressive
effect of miR-124. The lv-miR-124/5-8 F cell line after
transfected lv-Foxq1 was named lv-miR-124 + lv-Foxq1/
5-8 F. The expression level of Foxq1 was tested using
Real-time PCR and Western bolt (Figure 6I and J). CCK8
array and colony-forming assay showed that Foxq1 could
partially abrogate the effects mediated by miR-124 in lv-
miR-124 + lv-Foxq1/5-8 F cells (Figure 6E and F). At the
same time, the migration and invasion arrays showed
Figure 2 The ectopic expression of miR-124 suppressed the proliferation, migratory and invasive capacity of NPC cell. A, The expression
levels of miR-124 in 5-8 F and 6-10b cell lines were verified after tranfected with miR-124 mimics and miR-Ctrl. (B and C), Effect of miR-124 on
cell proliferation was measured by CCK-8 assay in 5-8 F and 6-10b cell lines. (E and F), The migrated and invasive cell numbers of NPC cells after
transfected with miR-124 mimics and miR-Ctrl. (G and H), The fields of migrated and invasive cells on the membrane (magnification × 100). Statistical
analysis was performed using the t-tests. The data represent the mean values of three independent experiments. *, P < 0.05, **, P < 0.01.
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vasion activity compared with the lv-Ctrl/5-8 F cells
(Figure 6G and H). The similar results were obtained
in lv-miR-124 + lv-Foxq1/6-10B cell lines (Additional
file 5: Figure S4A-F). Therefore, we showed that Foxq1
could partially rescue the suppression of miR-124 in
NPC cells.
MiR-124 and Foxq1 were inversely correlated in NPC
tissues
To further investigate the expression of Foxq1, 178 clinical
human primary NPC tissues and 55 non-cancer naso-
pharyngitis biopsy samples were tested for analyzing
the clinicopathologic significance. We found that the
average expression level of Foxq1 was up-regulated in
NPC tissue compared with non-cancer biopsy samples
(Figure 7A). Further analysis found that the Foxq1 ex-
pression of clinical I stage was the lowest in the clinical
stages (Figure 7B). In addition, we found that Foxq1expression was lower in stage T1, whereas stages T2-
T4 had higher levels, showing a significant correlation
of Foxq1 with T stage (Figure 7C). We then correlated
Foxq1 with the miR-124 expression levels in the same
NPC specimens. As shown in Figure 7E, significant inverse
correlation was observed when Foxq1 expression levels
were plotted against miR-124 expression levels (2-tailed
Spearman’s correlation, r = −0.5646; p < 0.001).
Immunohistochemistry (IHC) was also performed to
detect Foxq1 expression in 178 clinical NPC specimens
and 55 non-cancer nasopharyngitis biopsy samples.
Foxq1 was found to be predominantly overexpressed in
the cytoplasm and membranes of NPC cells and was less
expressed in non-cancer nasopharyngitis biopsy samples
(Figure 7D). Our data also showed that the Foxq1 ex-
pression was statistically higher than in non-cancer
biopsy samples. We found that Foxq1 expression was
lower in stage I, whereas stages II-IV had higher levels,
showing a significant correlation of Foxq1 with clinical
Figure 3 The ectopic of miR-124 affected cell cycle in the NPC cell lines in vitro and suppressed cell growth in vivo. A, The ectopic
expression of miR-124 arrest G0 + G1 phases and decreased S phase in 5-8 F and 6-10b compared with miR-Ctrl. B, Stably expression of miR-124
cell lines were evaluated using real time qPCR. C, Colonies were evaluated and values were reported as the ratio between lv-miR-124-infected
cells and lv-miR-Ctrl infected cells. D, Pictures of colony formation assay of lv-miR-124 infected 5-8 F and 6-10b cell lines. (E and F), 5-8 F cells
infected lv-miR-124 and lv-miR-Ctrl were injected subcutaneously into nude mice, at 15 days after implanted, lv-miR-124 infected 5-8 F cells
produced smaller tumors than control cells. The “F” figure showed the growth curve of tumors volumes. Each data point represents of 6 mice.
G, Picture showed the tumors after stripped. H, The weight of tumors compared with 5-8 F infected lv-miR-124 and lv-miR-Ctrl. I, Ki-67- and
PCNA-stained sections of transplanted tumors formed after orthotopic transplantation. Scale bars, 100 μm. Statistical analysis was performed
using the nonparametric tests. *, P < 0.05, **, P < 0.01.
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the miR-124 expression levels in the same NPC specimens.
As shown in Figure 7G, a significant inverse correlation
was observed when Foxq1 expression levels were plotted
against miR-124 expression levels (2-tailed Spearman’s cor-
relation, r = −0.6056; p < 0.0001).
Discussion
In this report, we identified for the first time that miR-
124 was markedly down-regulated in NPC cell lines and
clinical specimens. The ectopic expression of miR-124
suppressed the proliferative, migratory and invasive cap-
acities of NPC cells in vitro, and suppressed tumor
growth and metastasis in vivo. Moreover, we found thatthe expression of Foxq1 protein was down-regulated
after transfected lv-miR-124 in NPC cells by western
blot. By using Dual-luciferase assay, Foxq1 was identified
as a new direct and functional target of miR-124. Our re-
sults also showed that Foxq1 overexpression could rescue
partially the suppressive effect of miR-124, and we found a
negative correlation between miR-124 and Foxq1 expres-
sion in NPC tissues. These results supported that Foxq1
was a direct target gene of miR-124. Our study demon-
strated that miR-124 acts as a novel proliferation and me-
tastasis suppressor by targeting Foxq1 in NPC.
The ectopic expression of miR-124 is a frequently epige-
netically silenced tumor-suppressive microRNA in various
cancers [28-34]. The capability of cells to proliferate,
Figure 4 MiR-124 suppressed the lung and liver metastases of NPC cells in vivo. Groups of BALB/c nude mice were inoculated with
lv-miR-124/5-8 F or lv-Ctrl/5-8 F cells. The liver and lung metastases were monitored by GFP-based fluorescence imaging on day 25 after
inoculation (n = 5 per group). A, Lungs and livers were obtained from the mice of the lv-miR-124/5-8 F and lv-Ctrl/5-8 F groups. White
arrows indicate liver and lung metastases. B, Representative H&E sections of liver and lung. Scale bars in lung, 200 μm; scale bars in liver,
2 mm. (C and D), Numbers of the metastatic nodules in the liver and lungs after injected with lv-miR-124/5-8 F or lv-Ctrl/5-8 F cell. Statistical
analysis was performed using the nonparametric tests. *, P < 0.05, **, P < 0.01.
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in the process of tumorigenesis and progression. Many on-
cogenes and suppressor genes reportedly correlate with the
course of cancer initiation and progression [28]. In this
study, our results provided strong evidences that miR-124
inhibited the proliferation, migration and invasion of NPC
cells in vitro and in vivo. These results were consistent with
observations in breast cancer, hepatocellular carcinoma and
glioblastoma [28-34]. The suppressive capability suggested
that miR-124 functioned as a tumor-suppressive microRNA
in NPC.
Emerging evidence indicates that miR-124 is abnor-
mally expressed and has been implicated in several
tumors. Until now, several studies have demonstrated
that miR-124 was down-regulated and inversely corre-
lated with clinical characteristic and prognosis in breastcancer and colorectal cancer [28,35]. Our previous study
demonstrated that plasma miR-124 was down-regulated
in NPC. The present study is the first report to explore
the expression of miR-124 in NPC tissues. We found
that the expression level of miR-124 between NPC pa-
tient plasma and tissue decreased simultaneously. The
reduced expression of miR-124 in NPC tissues was in-
versely correlated with clinical stages, T stages and
marked the progression from locoregional tumors to
metastatic tumors. Recent reports have showed that
miRNAs which can be reliably isolated from human
plasma are stable in circulation, and can be used as a
diagnostic tool for early detection of NPC [11,36]. More
importantly, it is simple, effective, and non-invasive
blood-based biomarker which predicts the clinical be-
haviour of NPC and monitored therapeutic response
Figure 5 The ectopic miR-124 induced the expression of Foxq1 by directly targeting its 3′-UTR. A, Putative miR-124 binding site in the
3′-UTR region of Foxq1 and interspecies conservation of seed matching sequences (gray box). (B and C), The gene expression of Foxq1 in NPC
cells compared with NP69 cells by RT-qPCR and western bolt. D, The protein expression level of Foxq1 in lv-miR-124/5-8 F cell and lv-miR-124/6-10B
cell compared with control. E, Diagram of wt 3′-UTR and mut 3′-UTR of Foxq1 contained reporter constructs. F, Luciferase reporter assays in 5-8 F cells,
co-transfected of wt/mut 3′-UTR with miRNAs as indicated. Statistical analysis was performed using the t-tests. The data represent the mean values of three
independent experiments. *, P < 0.05, **, P < 0.01.
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the expression level of miR-124 between NPC patient
plasma and tissue changed in the same direction. The
reduced expression of miR-124 in NPC tissues was in-
versely correlated with clinical characteristic. For these
reasons, miR-124 could serve as an independent bio-
marker marker to identify patients with clinical charac-
teristic. However, further investigation is needed to
confirm the prognostic value of miR-124 as an effective
biomarker.
Foxq1 is a member of the FOX gene family. FOX
genes are involved in embryonic development, cell cycle
regulation, tissue-specific gene expression, cell signaling,
and tumorigenesis [22,37]. Recent studies have clearly
showed that Foxq1 was implicated in tumor proliferation
and metastasis in colorectal cancer, glioblastoma, breast
cancer and hepatocellular carcinoma [26,27,38,39]. Foxq1was a prognostic marker for patients in gastric cancer and
hepatocellular carcinoma [40,41]. However, the role of
Foxq1 is rarely known in NPC. Our results demonstrated
for the first time that Foxq1 was overexpressed in NPC cell
lines and NPC tissues, consistent with the published data
[27,39,40,42]. In NPC tissues, Foxq1 expression increased
with clinical stage, T stage. Functional studies also con-
firmed that down-regulation of Foxq1 suppressed cell pro-
liferation, migration and invasion in vitro. These results
implied that Foxq1 was a potential oncogene in develop-
ment and progression of NPC. Nonetheless, the molecular
pathological mechanism of Foxq1 in NPC was still un-
known. A report showed that Foxq1 may be a novel target
of the Wnt pathway in solid tumors and Foxq1 expression
was associated with genes as markers for proliferation
(MKI67, TPX2, AURKA) and epithelial-mesenchymal tran-
sition (VIM, SNAI1, ZEB2, CDH2) [42]. Then, we tested
Figure 6 The suppression of down-regulated of FOXQ1 was consistent with the suppression of the ectopic miR-124 and overexpression of
FOXQ1 could rescue partially the suppression of miR-124. A, 5-8 F cells were transfected with siRNA-Foxq1 or miR-124 mimics. Effect of siRNA-Foxq1
or miR-124 on cell proliferation was measured by CCK-8 assay in 5-8 F lines. (B and C), The migrated and invasive cell numbers of NPC cells. D, The protein
expression level of Foxq1 was detected after transfect with siRNA-Foxq1 or miR-124 mimics. (E and F), Effect of over-expression regulated
Foxq1 in lv-miR-124/5-8 F cells on cell proliferation and tablet cloning ability were measured. (G and H), Effect of up-regulated Foxq1 in
lv-miR-124/5-8 F cells on cell migration and invasion were test. (I and J), Stable expression of Foxq1 in lv-miR-124/5-8 F cells (lv-Foxq1/lv-miR-124/5-8 F)
was constructed. Statistical analysis was performed using the t-tests. The data represent the mean values of three independent experiments. **, P < 0.01.
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(MKI67, SNAI1 and ZEB2) were down-regulated after
siRNA- Foxq1 transfection in NPC cells (data not shown).
Further study is needed to clearly illustrate the tumorigenic
mechanisms of Foxq1.Conclusions
This study identifies miR-124 as a growth suppressive
miRNA in human NPC, at least, partly through repres-
sion of Foxq1. MiR-124 could serve as an independent
biomarker marker to identify patients with clinical char-
acteristic. Although miRNA-based therapeutics is still in
their infancy, our findings on miR-124 are encouragingand suggest that this miRNA could be a potential target
for the treatment of NPC in future.
Methods
Clinical specimens
Tumors biopsy specimens (n = 178) and non-cancer
nasopharyngitis biopsy samples (n = 55) were obtained
from patients in Nanfang Hospital (Southern Medical
University, Guangzhou, China) and were frozen in liquid
nitrogen for further study. Informed written consent was
obtained from each patient. All samples were pathologic-
ally confirmed as NPC. The TNM classification was
according to the definitions of the seventh edition of
the UICC-American Joint Committee on Cancer staging
Figure 7 Mir-124 and Foxq1 are inversely correlated in NPC tissues. A, The average expression level of Foxq1 in human NPC specimens
compared with non-cancer biopsy samples. B, The Foxq1 expression of clinicalIstage had lower expression than in the IVstage. C, Foxq1 expression was
lower in stage T1, whereas stages T2-T4 had higher levels. D, Representative IHC for Foxq1 in non-cancer biopsy samples and NPC specimen with different
clinical stages. E, In the mRNA levels, a significant inverse correlation was observed after correlated Foxq1 with the miR-124 expression levels in the 178
NPC specimens. F, Statistical quantification of the IHC scores of Foxq1 between non-cancer biopsy samples and NPC specimen with different clinical stages.
Scale bars, 100 μm. G, A scatter diagram shows an inverse correlation between miR-124 and Foxq1 expression in the same set of NPC tissue (Spearman’s
correlation analysis, r = −0.6056; p < 0.0001).Statistical analysis was performed using the nonparametric tests (A) and the one-way ANOVA
(B, C, E, F). *, P < 0.05, **, P < 0.01.
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Ethics Committee of Nanfang Hospital and registered in
Clinical.trials.gov (ID: NCT01171235).
Cell culture
Human nasopharyngeal carcinoma cell lines such as
5-8 F, 6-10B, CNE1, CNE2, Sune-1, Hone-1 and C666-
1 were cultured in RPMI-1640 medium (HyClone,
Thermo scientific Inc, China). HEK 293 T cell line
(Cell Bank of Chinese Academy of Science in Shanghai,
China) was cultured in DMEM/High Glucose medium
(HyClone, Thermo scientific Inc, China). The above
cell lines were supplemented with 10% fetal bovine
serum (FBS, HyClone, Thermo scientific Inc, China).The immortalized nasopharyngeal epithelial cell NP69
(Cancer Research Center, Southern medical university,
China) was cultured as the control cell line in
Keratinocyte-SFM (GIBICO, Life Technologies corpor-
ation, USA).
RNA isolation, reverse transcription, and quantitative
Real-time PCR
Total RNA was extracted from the samples using
RNAiso Plus (TAKARA, Shiga, Japan) and reversely
transcribed to cDNA using the All-in-One First-Strand
cDNA Synthesis kit (GeneCopoeia Inc., USA). Quantita-
tive Real-time PCR (qPCR) was performed using All-in-
OneTM qPCR Mix (Applied GeneCopoeia Inc., USA) on
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used as miRs and miRNA endogenous control respect-
ively. All samples were normalized to the internal con-
trol, and the relative expression levels of miR-124 and
Foxq1 were calculated using relative quantification assay.
Primer sequences for qRT-PCR were displayed in
Additional file 6: Table S2.
Oligo-nucleotide transfection
MiR-124 mimics, miR-Ctrl, Foxq1 siRNAs and Foxq1-
Ctrl were synthesized from Gene-pharma (Shanghai,
China). RNA oligonucleotides were transfected by lipo-
fectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA).
Plasmid construction and stable transfection
To obtain stable cell lines to overexpress miR-124,
pre-miR-124 was cloned into the pLVTHM lentiviral
vector, and the recombinant plasmid was named as
lv-miR-124. The lentivial vectors and packing sys-
tem (psPAX2 and PMD2G) were co-transfected in
HEK293T cells by calium phosphate precipitation.
Then lentivial virus was collected to infect the 5-8 F
and 6-10B cell lines.
The 3′-UTR of Foxq1 was amplified from human
genomic DNA and cloned into the psicheck.2 vector
(Promega, USA). The mutation of the 3′-UTR of Foxq1
was carried out using site-directed mutagenesis kit
(Invitrogen, Carlsbad, CA, USA).
The lentivial viruses to overexpress Foxq1 were pur-
chased from Genechem (Shanghai, China). Then they
were used to infect 5-8 F cell lines which stably overex-
pressed miR-124. The transfected cells were selected by
Flow Cytometry.
Bioinformatics analysis
The probable target genes of miR-124 were predicted
using three microRNA target database (PicTar, TargetS-
can and PITA), and the selected targets gene were vali-
dated by RT-qPCR and Western Blot.
Dual-luciferase assay
Cells were cultured in 24-well plates for Dual-luciferase
report system. Cells were co-transfected with 200 ng
Wild or Mutant type reporter plasmid and 20 nmol
miRNA or anti-miRNA using lipofectamine 2000 re-
agent (Invitrogen). Cells were harvested and lysed after
24 hours transfection. The firefly and Renilla luciferase
activities were measured using the Dual-Glo luciferase re-
porter assay kit (Promega, Madison, WI, USA).
Cell proliferation and colony-formation assay
To determine the effect of miR-124 on cell proliferation,
cells with stable overexpression of miR-124 were seeded
into 96 wells plates at a density of 1 × 103 cells/well withfive replicate wells. The effect of miR-124 on cell growth
and viability was determined by Cell counting kit 8 assay
as described previously [43]. To measure colony-forming
activity, cells were counted and seeded into 12-well
plates at 100 cells per well. Twelve days after seeding,
the numbers of colonies containing more than 50 cells
were stained with crystal violet and counted.
Migration and invasion assays in vitro
Transwell migration assay and invasion assay were con-
ducted to determine the functional effects of miR-124 on
cell migration and invasion as described previously [14].
Cell cycle assays
To determine cell cycle distribution, the cells were plated
in 6-well plates and transfected with miRNA mimics or
siRNA duplexes. After transfection, the cells were har-
vested, treated with cell cycle detection kit (keygentec
Nanjing China) and tested using a FACSCalibur instrument
(Becton Dickinson, CA, USA). The data were analyzed
using the CellQuest Pro software (BD Biosciences).
Tumor xenograft model and tumor metastasis assay
in vivo
Twelve female BALB/C nude mice about four to five-
week-old were purchased from Centre of Laboratory
Animal of Southern Medical University, and the animal
protocol was approved by Institutional Animal Care and
Use Committee of Southern Medical University. Twelve
nude mice were randomly divided into two groups. 1 ×
105 lv-miR-124/5-8 F or lv-miR-Ctrl/5-8 F cells were
injected into the dorsal flank of each mouse. Tumor size
was measured every other day. Mice were sacrificed and
tumors were dissected and weighed. Tumor volumes
were calculated as follows: volume = (D × d2)/2, where
D = the longest diameter and d = the shortest diameter.
For tumor metastasis assay in vivo, we used a murine
model of NPC metastasis successfully established previ-
ously [44]. To establish this model, we inoculated NPC
cells into the liver as a single nodule, which would sub-
sequently metastasized to other parts of the liver and the
lung. Ten nude mice were randomly divided into two
groups. 1 × 106 lv-miR-124/5-8 F or lv-miR-Ctrl/5-8 F
cells were injected into the liver of each mouse. The
mice were killed and autopsied on day 25, and the inci-
dence of lung or liver metastasis were recorded.
Western blot
Protein lysates extracted from cell lines were separated
by 10% SDS-PAGE, and electrophoretically transferred
to PVDF (polyvinylidene difluoride) membrane (Millipore).
Then, the membrane was incubated with goat polyclonal
antibody against human Foxq1 (WuXi PharmaTech
Cayman China) followed by HRP (horseradish peroxidase)-
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and detected by chemiluminescence. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as a protein-
loading control.
Immunohistochemical analysis
Formalin-fixed, paraffin-embedded tissues of trans-
planted tumors were sectioned at 4-mm thickness and
analyzed for anti-Foxq1 primary antibody (Abcam Ltd,
Cambridge, UK), anti- Ki-67 primary antibody, and anti-
PCNA primary antibody (Cell Signaling Technology, Inc.
USA). Visualization was achieved using the EnVisionþ per-
oxidase system (Dako). A sample was considered positive if
more than 50% of the tumor cells retained nuclear staining,
and 5 fields were randomly selected according to semi-
quantitative scales. The intensity of staining was scored
manually: negative (−), weak positive (+), medium positive
(++), strong positive (+++). Data recording and analysis by
2 independent experienced pathologists, and only tumor
cells were scored.
Statistical analysis
Statistical analyses were conducted using spss13.0 statis-
tical software. All experiments were performed for three
times. The data are shown as the mean ± SEM unless
otherwise noted. Two-tailed Student’s t test was used
for comparison of two independent groups. A one-way
ANOVA analysis of variance was used to compare mul-
tiple groups. MiR-124 and Foxq1 expressions between
tumor and control specimens were analyzed by a Mann–
Whitney U test. The relationship between miR-124 and
Foxq1 was analyzed using Spearman’s correlation analysis.
P values of <0.05 were considered statistically significant.
Additional files
Additional file 1: Figure S1. The expression levels of miR-124 in tumor
xenograft model and tumor metastasis assay in vivo. A, The expression
levels of Lv-miR-124/5-8F compared with Lv-miR-Ctrl/5-8F in tumorigenesis in
murine models. B, The expression levels of Lv-miR-124/5-8F compared with
Lv-miR-Ctrl/5-8F in tumor metastasis murine models. Statistical analysis was
performed using the t-tests. The data represent the mean values of three
independent experiments. **, P<0.01.
Additional file 2: Table S1. Immunohistochemical analysis of Ki-67 and
662 PCNA expression in transplanted tumors of nude mice.
Additional file 3: Figure S2. The ectopic miR-124 induced the expression
of Foxq1 by directly targeting its 3′-UTR. A, The 27 possible target genes of
mir-124 were predicted by bioinformatic analysis. Results of qRT-PCR showed
the relative expression of Foxq1 was the most significant down-regulated in
lv-miR-124/5-8F cells compared with lv-miR-Ctrl/5-8F. B, The mRNA expression
level of Foxq1 in lv-miR-124/5-8F cell and lv-miR-124/6-10B cell compared with
control cells. C, Luciferase reporter assays in HK293T cells, co-transfected
of wt/mut 3′-UTR with miRNAs as indicated. Statistical analysis was
performed using the t-tests. The data represent the mean values of
three independent experiments.
*, P<0.05, **, P<0.01.
Additional file 4: Figure S3. Down-regulated of Foxq1 inhibited cell
proliferation, migration and invasion and the suppression of down-regulatedof Foxq1 was consistent with the suppression of the ectopic miR-124. A, The
mRNA expression levels of Foxq1 in 5-8F cells after tranfected with Foxq1
siRNA and Ctrl-siRNA. B, Effect of down-regulated Foxq1 on cell proliferation
was measured by CCK-8 assay used 5-8F cell lines. (C and D), The migratory
and invasive cell numbers were detected after tranfected with Foxq1 siRNA
and Ctrl-siRNA. E, 6-10B cells were transfected with siRNA-Foxq1 or miR-124
mimics. Effect of siRNA-Foxq1 or miR-124 on cell proliferation was measured
by CCK-8 assay in 6-10B lines. (F and G), The migrated and invasive
cell numbers of 6-10B cells. Statistical analysis was performed using
the t-tests. The data represent the mean values of three independent
experiments. *, P<0.05, **, P<0.01.
Additional file 5: Figure S4. Over-expression of Foxq1 could rescue
partially the suppression of miR-124 in 6-10B cells. (A and B), Effect of
up-regulated Foxq1 in lv-miR-124/5-8F cells (lv-Foxq1/lv-miR-124/6-10B)
on cell proliferation and tablet cloning ability were measured. (C and D),
Effect of up-regulated Foxq1 in lv-miR-124/5-8F cells on cell migration
and invasion was test. (E and F), Stable expression of Foxq1 in lv-miR-
124/6-10B cells (lv-Foxq1/lv-miR-124/6-10B) was constructed. Statistical
analysis was performed using the t-tests. The data represent the mean
values of three independent experiments. **, P<0.01.
Additional file 6: Table S2. Primers was used in this study.
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